

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Regenerative Medicine International Limited**

**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

### **CLARIFICATION ANNOUNCEMENT**

This announcement is made by China Regenerative Medicine International Limited (the “**Company**”, together with its subsidiaries the “**Group**”), and is intended to clarify certain statements reported by the press recently about the Company.

The board of directors (the “**Board**”) of the Company has noted some press articles (the “**Press Articles**”) which appeared in various newspapers dated 12 April 2018 and 13 April 2018 in Hong Kong.

In the Press Articles, it was reported that Mr. Chen Chunguo (“**Mr. Chen**”), an executive Director and chief executive officer of the Company, made the following statements (the “**Statements**”):

- (1) the Company is currently negotiating on:
  - (a) the proposed acquisitions of three (3) target companies in the People’s Republic of China (the “**PRC**”) principally engaged in aesthetic medicine and health channels, with a budgeted consideration of RMB500 million in total; and
  - (b) the proposed acquisitions of two (2) overseas target companies principally engaged in gene and vitro repairing, and organ regeneration, with a budgeted consideration ranging from RMB500 million to RMB600 million in total;
- (2) the Company will set up fifteen (15) cell storage centers, and provide RMB20 million annually to universities for research and development (“**R&D**”);
- (3) the Company expects its R&D expenses will amount to approximately 3 to 4% of its revenue for the year ending 31 December 2018;

- (4) the Company expects to double its revenue to RMB1 billion for the year ending 31 December 2018;
- (5) the Company expects to turn its financial results into profit from loss for the year ending 31 December 2018; and
- (6) the Company would apply for a transfer of listing of its shares from GEM to the Main Board as soon as possible if its financial results meet the regulatory requirements.

The Company would like to clarify that the Statements were Mr. Chen's own personal views and aspirations for the future development of the Company and its management team. Such information is not intended to form part of the information to be published by the Company in relation to its business, and does not reflect or represent the Company's future operations or business plans. To this end, the Board confirms that the Statements do not represent the opinions of the Company.

The Company wishes to stress that, as of the date hereof:

- (1) it has not entered into any formal or definitive agreement in relation to any proposed acquisition which has not been previously disclosed;
- (2) it does not have any plan to set up additional cell storage centers at this stage;
- (3) save as disclosed in the Company's 2017 annual report published on 28 March 2018, the Company does not have any plan to provide funds to universities for R&D purposes;
- (4) it has not made any forecast as to the Company's revenue or profit for the year ending 31 December 2018 or any future financial period; and
- (5) it does not have any plan to transfer its shares from GEM to the Main Board.

While the Company is consistently evaluating potential acquisition opportunities, the Company does not, currently, have any information that is material or relevant to the shareholders of the Company (the "**Shareholders**") or potential investors for making an informed judgment on whether to make an investment in the Company. The Board considers that the information contained in the Press Articles does not constitute discloseable nor inside information of the Company under Rule 13.09(2) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and there is no other information that needs to be brought to the attention of the Stock Exchange or the Shareholders at this stage.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Chen Chunguo**  
*Executive Director*

Hong Kong, 16 April 2018

*As at the date of this announcement, the executive Directors are Mr. Chen Chunguo and Dr. Ray Yip; the non-executive Directors are Professor Cui Zhanfeng, PhD, DSc, FREng and Professor Xiong Chengyu; and the independent non-executive Directors are Mr. Chan Bing Woon, SBS, JP, Mr. Wong Yiu Kit Ernest, Mr. Pang Chung Fai Benny and Dr. Fang Jun.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcement” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of the publication and will be published on the website of the Company at [www.crmi.hk](http://www.crmi.hk).*